Schizophrenia Clinical Trial
Official title:
Clozapine Fixed Dose Steady State Plasma Levels and the Relationship to the Polymorphism of CYP1A2, CYP3A4, CYP3A5 and CYP2D6 in Clinically Stable Schizophrenic Adult Patients
Verified date | October 2017 |
Source | Tirat Carmel Mental Health Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Approximately 30-60% of all schizophrenia patients who fail to respond to typical
antipsychotics may respond to Clozapine. Clozapine has long been considered the "gold
standard" within the atypical neuroleptic spectrum, backed by years of clinical experience
and research, but uncertainties remain in some aspects of this drug. One such question is the
link between dose, blood levels and patient clinical response. The Clozapine therapeutic
plasma levels range between 250 - 450 ng/mL creating difficulties in using these results in
routine clinical practice. Approximately 30% - 51% of "treatment-resistant schizophrenia"
patients do not fully respond to Clozapine, a poorly understood phenomenon. Factors relevant
to Clozapine-resistance include co-morbidity, drug misuse, poor adherence, inadequate
duration of treatment and inadequate dose/plasma-levels. Pharmacogenetic factors such as
different polymorphisms in involved genes may play a role. Pharmacodynamic and genetic data
appear important in determining the clinical response to Clozapine. Clozapine-treated
patients possessing different 3A4 polymorphisms, may respond differently as compared to other
patients having normal 3A4 alleles. Recently, the CYP2D6 has also been involved in this drug
metabolic pathway. Population pharmacokinetics of clozapine evaluated with the nonparametric
maximum likelihood method. This pharmacogenetic explanation/hypothesis may explain Clozapine-
resistance in schizophrenics.
The high variability in plasma levels requires a large study in order to be able to determine
correlation between clinical efficacy and plasma levels and genotyping. A preliminary study
will enable power analysis and adequate determination of sample size.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - DSM-IV criteria for schizophrenia (American Psychiatric Association 2000) - All clozapine mono-therapy patients (only 300 mg/day) who respond to treatment and achieved symptomatic remission (45, 46) and were stable for at least 3 month will be included - No change in benzodiazepine medications for the trial period. - Legal ability and willingness to sign an informed consent form for participation in the study. Exclusion Criteria: - Evidence of serious neurologic or endocrine disorder, for example severe head trauma, seizure disorder, dementia, Cushing's disease, thyroid disorder, mental retardation, alcohol or drug abuse, substance dependence (other than nicotine dependence), or presenting symptoms likely substance- induced, as judged by a study physician. - Unstable medical illness or neurologic illness (seizures, CVA); breast, uterine, or ovarian cancer. - Pregnant women, use of oral contraceptives or other hormonal supplementation such as estrogen. [Female patients will also have a pregnancy test.]. |
Country | Name | City | State |
---|---|---|---|
Israel | Tirat Carmel Mental Health Center | Tirat Carmel |
Lead Sponsor | Collaborator |
---|---|
Tirat Carmel Mental Health Center | Beersheva Mental Health Center, Ben-Gurion University of the Negev, HaEmek Medical Center, Israel, Sha’ar Menashe Mental Health Center, Technion, Israel Institute of Technology, The Nazareth Hospital, Israel |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clozapine steady state plasma level | 3 month | ||
Secondary | Polymorphism of CYP1A2, CYP3A4, CYP3A5 and CYP2D6 in clinically stable schizophrenic adult patients | Once |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |